Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia (Q44392561)

2 December 2017

Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia (English)

1 reference

2 December 2017

0 references

1 reference

Yuichiro Amano

1

1 reference

2 December 2017

Tomoyuki Nishimoto

2

1 reference

2 December 2017

Ryu ichi Tozawa

3

1 reference

2 December 2017

Eiichiro Ishikawa

4

1 reference

2 December 2017

Yoshimi Imura

5

1 reference

2 December 2017

Yasuo Sugiyama

6

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

European Journal of Pharmacology

2 December 2017

1 reference

2 December 2017

466

1 reference

2 December 2017

1-2

1 reference

2 December 2017

155-161

1 reference

Cadiovascular complications of homozygous familial hypercholesterolaemia

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Genetic basis of lipoprotein disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

A mouse model with features of familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901549-8

10.1016/S0014-2999(03)01549-8

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference